T cell engagers with improved therapeutic index and sustained anti-tumor activity
28 Oct 2024
Bi/Multispecifics
- Need for costimulation through CD28, CD137 or cytokines.
- Tailoring costimulatory signals to tumor indications.
- Format considerations for costimulatory signals: drug combinations vs multi specifics.
- Dosing schedule to prevent T cell exhaustion.
- Conditionally active T cell engagers.
Industry Experts
